Preclinical studies have confirmed that [68Ga]Ga-P17-079 in both mouse prostate tumors and osseogenic metastases has high uptake and prolonged retention, which enables [68Ga]Ga-P17-079 to be fully absorbed by the lesions, and it is possible to detect bone metastases, prostate cancer primary sites, lymph node metastases and organ metastases at the same time in a single examination. It is a potential "killing two birds with one stone" imaging agent. At this stage, the clinical study of [68Ga]Ga-P17-079 in the diagnosis and treatment of metastatic prostate cancer as a self-made preparation is planned to be carried out in our hospital to further verify its clinical application value.

Inclusion Criteria:

• Male aged 18-85 years, expected survival ≥12 weeks.
• Patients who have not undergone chemoradiotherapy, feasible surgery or biopsy to obtain a pathological diagnosis or are highly suspected of malignancy according to clinical diagnostic criteria.
• At least one measurable target lesion was present according to RECIST1.1 criteria.
• Obtain written informed consent and be able to follow up

Exclusion Criteria:

• Severe abnormal liver and kidney function
• Fertile subjects will need to use effective contraception during the study
• Unable to lie flat for half an hour
• Refused to join this clinical investigator
• Suffering from claustrophobia or other mental illness
• Other conditions deemed unsuitable for participation in the trial